Abstrakt

Przypisy

• 1. Abbate M., Zoja C., Remuzzi G.: How does proteinuria cause progressiverenal damage? J. Am. Soc. Nephrol., 2006; 17: 2974-2984
  Google Scholar
• 2. Akilesh S., Huber T.B., Wu H., Wang G., Hartleben B., Kopp J.B.,Miner J.H., Roopenian D.C., Unanue E.R., Shaw A.S.: Podocytes useFcRn to clear IgG from the glomerular basement membrane. Proc.Natl. Acad. Sci. USA, 2008; 105: 967-972
  Google Scholar
• 3. Alachkar N., Wei C., Arend L.J., Jackson A.M., Racusen L.C., FornoniA., Burke G., Rabb H., Kakkad K., Reiser J., Estrella M.M.: Podocyteeffacement closely links to suPAR levels at time of posttransplantationfocal segmental glomerulosclerosis occurrence and improveswith therapy. Transplantation, 2013; 96: 649-656
  Google Scholar
• 4. Ambalavanan S., Fauvel J.P., Sibley R.K.. Myers B.D.: Mechanismof the antiproteinuric effect of cyclosporine in membranous nephropathy.J. Am. Soc. Nephrol., 1996; 7: 290-298
  Google Scholar
• 5. Anderson D.R., Grillo-López A., Varns C., Chambers K.S., HannaN.: Targeted anti-cancer therapy using rituximab, a chimaeric anti–CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin›s B–cell lymphoma. Biochem. Soc. Trans., 1997; 25: 705-708
  Google Scholar
• 6. Appel D., Kershaw D.B., Smeets B., Yuan G., Fuss A., Frye B., ElgerM., Kriz W., Floege J., Moeller M.J.: Recruitment of podocytes fromglomerular parietal epithelial cells. J. Am. Soc. Nephrol., 2009; 20:333-343
  Google Scholar
• 7. Asanuma K., Yanagida-Asanuma E., Faul C., Tomino Y., Kim K.,Mundel P.: Synaptopodin orchestrates actin organization and cellmotility via regulation of RhoA signalling. Nat. Cell Biol., 2006; 8:485-491
  Google Scholar
• 8. Bakker W.W., van Dael C.M., Pierik L.J., van Wijk J.A., Nauta J.,Borghuis T., Kapojos J.J.: Altered activity of plasma hemopexin inpatients with minimal change disease in relapse. Pediatr. Nephrol.,2005; 20: 1410-1415
  Google Scholar
• 9. Banas M.C., Banas B., Hudkins K.L., Wietecha T.A., Iyoda M., BockE., Hauser P., Pippin J.W., Shankland S.J., Smith K.D., Stoelcker B., LiuG., Gröne H.J., Krämer B.K., Alpers C.E.: TLR4 links podocytes withthe innate immune system to mediate glomerular injury. J. Am. SocNephrol., 2008; 19: 704-713
  Google Scholar
• 10. Berger K., Schulte K., Boor P., Kuppe C., van Kuppevelt T.H., FloegeJ., Smeets B., Moeller M.J.: The regenerative potential of parietalepithelial cells in adult mice. J. Am. Soc. Nephrol., 2014; 25: 693-705
  Google Scholar
• 11. Bezombes C., Grazide S., Garret C., Fabre C., Quillet-Mary A.,Müller S., Jaffrézou J.P., Laurent G.: Rituximab antiproliferative effectin B-lymphoma cells is associated with acid-sphingomyelinaseactivation in raft microdomains. Blood, 2004; 104: 1166-1173
  Google Scholar
• 12. Blasi F., Carmeliet P.: uPAR: a versatile signalling orchestrator.Nat. Rev. Mol. Cell Biol., 2002; 3: 932-943 13 Brinkkoetter P.T., Ising C., Benzing T.: The role of the podocytein albumin filtration. Nat. Rev. Nephrol., 2013; 9: 328-336
  Google Scholar
• 13. act on glomerular visceral epithelial cells. J. Am. Soc. Nephrol.,2000; 11: 413-422
  Google Scholar
• 14. Cara-Fuentes G., Wei C., Segarra A., Ishimoto T., Rivard C., JohnsonR.J., Reiser J., Garin E.H.: CD80 and suPAR in patients with minimalchange disease and focal segmental glomerulosclerosis: diagnosticand pathogenic significance. Pediatr. Nephrol., 2014; 29:1363-1371
  Google Scholar
• 15. Chan A.C.: Rituximab’s new therapeutic target: the podocyteactin cytoskeleton. Sci. Transl. Med., 2011; 3: 85ps21
  Google Scholar
• 16. Charbit M., Gubler M.C., Dechaux M., Gagnadoux M.F., GrünfeldJ.P., Niaudet P.: Cyclosporin therapy in patients with Alport syndrome.Pediatr. Nephrol., 2007; 22: 57-63
  Google Scholar
• 17. Chen D., Jefferson B., Harvey S.J., Zheng K., Gartley C.J., JacobsR.M., Thorner P.S.: Cyclosporine a slows the progressive renal diseaseof alport syndrome (X-linked hereditary nephritis): results froma canine model. J. Am. Soc. Nephrol., 2003; 14: 690-698
  Google Scholar
• 18. Cheung P.K., Klok P.A., Baller J.F., Bakker W.W.: Induction ofexperimental proteinuria in vivo following infusion of human plasmahemopexin. Kidney Int., 2000; 57: 1512-1520
  Google Scholar
• 19. Cho M.H., Hong E.H., Lee T.H., Ko C.W.: Pathophysiology of minimalchange nephrotic syndrome and focal segmental glomerulosclerosis.Nephrology, 2007; 12 (Suppl. 3): S11-S14
  Google Scholar
• 20. Chugh S.S., Clement L.C., Macé C.: New insights into humanminimal change disease: lessons from animal models. Am. J. KidneyDis., 2012; 59: 284-292
  Google Scholar
• 21. Clement L.C., Avila-Casado C., Macé C., Soria E., Bakker W.W.,Kersten S., Chugh S.S.: Podocyte-secreted angiopoietin-like-4 mediatesproteinuria in glucocorticoid-sensitive nephrotic syndrome.Nat. Med., 2011; 17: 117-122
  Google Scholar
• 22. Clement L.C., Macé C., Avila-Casado C., Joles J.A., Kersten S.,Chugh S.S.: Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemiain nephrotic syndrome. Nat. Med., 2014; 20: 37-46
  Google Scholar
• 23. Coutinho A.E., Chapman K.E.: The anti-inflammatory and immunosuppressiveeffects of glucocorticoids, recent developments andmechanistic insights. Mol. Cell. Endocrinol., 2011; 335: 2-13
  Google Scholar
• 24. Coward R.J., Foster R.R., Patton D., Ni L., Lennon R., Bates D.O.,Harper S.J., Mathieson P.W., Saleem M.A.: Nephrotic plasma altersslit diaphragm-dependent signaling and translocates nephrin, Podocin,and CD2 associated protein in cultured human podocytes. J.Am. Soc. Nephrol., 2005; 16: 629-637
  Google Scholar
• 25. D›Agati V.D.: Podocyte injury in focal segmental glomerulosclerosis:lessons from animal models (a play in five acts). KidneyInt., 2008; 73: 399-406
  Google Scholar
• 26. Dijkman H.B., Gerlofs-Nijland M.E., van der Laak J.A., WetzelsJ.F., Groenen P.J., Assmann K.J.: Podocyte changes after induction ofacute albuminuria in mice by anti-aminopeptidase A mAb. NephronExp. Nephrol., 2003; 94: e85-e93
  Google Scholar
• 27. Ding W.Y., Saleem M.A.: Current concepts of the podocyte innephrotic syndrome. Kidney Res. Clin. Pract., 2012; 31: 87-93
  Google Scholar
• 28. Doublier S., Musante L., Lupia E., Candiano G., Spatola T., CaridiG., Zennaro C., Carraro M., Ghiggeri G.M., Camussi G.: Direct effectof plasma permeability factors from patients with idiopatic FSGS onnephrin and podocin expression in human podocytes. Int. J. Mol.Med., 2005; 16: 49-58
  Google Scholar
• 29. Eddy A.A., Symons J.M.: Nephrotic syndrome in childhood. Lancet,2003; 362: 629-639
  Google Scholar
• 30. Eugen-Olsen J., Andersen O., Linneberg A., Ladelund S., Hansen T.W.,Langkilde A., Petersen J., Pielak T., Moller L.N., Jeppesen J., Lyngbaek S.,Fenger M., Olsen M.H., Hildebrandt P.R., Borch-Johnsen K., JorgensenT., Haugaard S.B.: Circulating soluble urokinase plasminogen activatorreceptor predicts cancer, cardiovascular disease, diabetes and mortalityin the general population. J. Intern. Med., 2010; 268: 296-308
  Google Scholar
• 31. Faul C., Donnelly M., Merscher-Gomez S., Chang Y.H., Franz S.,Delfgaauw J., Chang J.M., Choi H.Y., Campbell K.N., Kim K., Reiser J.,Mundel P.: The actin cytoskeleton of kidney podocytes is a directtarget of the antiproteinuric effect of cyclosporine A. Nat. Med.,2008; 14: 931-938
  Google Scholar
• 32. Franco Palacios C.R., Lieske J.C., Wadei H.M., Rule A.D., FervenzaF.C., Voskoboev N., Garovic V.D., Zand L., Stegall M.D., Cosio F.G.,Amer H.: Urine but not serum soluble urokinase receptor (suPAR)may identify cases of recurrent FSGS in kidney transplant candidates.Transplantation, 2013; 96: 394-399
  Google Scholar
• 33. Gbadegesin R., Lavin P., Foreman J., Winn M.: Pathogenesis andtherapy of focal segmental glomerulosclerosis: an update. Pediatr.Nephrol., 2011; 26: 1001-1015
  Google Scholar
• 34. George K.S., Wu S.: Lipid raft: a floating island of death or survival.Toxicol. Appl. Pharmacol., 2012; 259: 311-319
  Google Scholar
• 35. Gohh R.Y., Yango A.F., Morrissey P.E., Monaco A.P., Gautam A.,Sharma M., McCarthy E.T., Savin V.J.: Preemptive plasmapheresis andrecurrence of FSGS in high-risk renal transplant recipients. Am. J.Transplant., 2005; 5: 2907-2912
  Google Scholar
• 36. Goldwich A., Burkard M., Olke M., Daniel C., Amann K., Hugo C.,Kurts C., Steinkasserer A., Gessner A.: Podocytes are nonhematopoieticprofessional antigen-presenting cells. J. Am. Soc. Nephrol.,2013; 24: 906-916
  Google Scholar
• 37. Grahammer F., Schell C., Huber T.B.: The podocyte slit diaphragm– from a thin grey line to a complex signalling hub. Nat. Rev.Nephrol., 2013; 9: 587-598
  Google Scholar
• 38. Gürcan H.M., Keskin D.B., Stern J.N., Nitzberg M.A., Shekhani H.,Ahmed A.R.: A review of the current use of rituximab in autoimmunediseases. Int. Immunopharmacol., 2009; 9: 10-25
  Google Scholar
• 39. Gurkan S., Cabinian A., Lopez V., Bhaumik M., Chang J.M., RabsonA.B., Mundel P.: Inhibition of type I interferon signalling preventsTLR ligand-mediated proteinuria. J. Pathol., 2013; 231: 248-256
  Google Scholar
• 40. Haas M., Meehan S.M., Karrison T.G., Spargo B.H.: Changingetiologies of unexplained adult nephrotic syndrome: a comparisonof renal biopsy findings from 1976-1979 and 1995-1997. Am. J. KidneyDis., 1997; 30: 621-631
  Google Scholar
• 41. Haraldsson B., Nyström J., Deen W.M.: Properties of the glomerularbarrier and mechanisms of proteinuria. Physiol. Rev., 2008;88: 451-487
  Google Scholar
• 42. Hingorani S.R., Finn L.S., Kowalewska J., McDonald R.A., EddyA.A.: Expression of nephrin in acquired forms of nephrotic syndromein childhood. Pediatr. Nephrol., 2004; 19: 300-305
  Google Scholar
• 43. Hogan P.G., Chen L., Nardone J., Rao A.: Transcriptional regulationby calcium, calcineurin, and NFAT. Genes Dev., 2003; 17: 2205-2232
  Google Scholar
• 44. Inagi R., Nangaku M., Onogi H., Ueyama H., Kitao Y., NakazatoK., Ogawa S., Kurokawa K., Couser W.G., Miyata T.: Involvementof endoplasmic reticulum (ER) stress in podocyte injury inducedby excessive protein accumulation. Kidney Int., 2005; 68: 2639-2650
  Google Scholar
• 45. Ishimoto T., Cara-Fuentes G., Wang H., Shimada M., WasserfallC.H., Winter W.E., Rivard C.J., Araya C.E., Saleem M.A., MathiesonP.W., Johnson R.J., Garin E.H.: Serum from minimal change patientsin relapse increases CD80 expression in cultured podocytes. Pediatr.Nephrol., 2013; 28: 1803-1812
  Google Scholar
• 46. Jefferson J.A., Alpers C.E., Shankland S.J.: Podocyte biology forthe bedside. Am. J. Kidney Dis., 2011; 58: 835-845
  Google Scholar
• 47. Kadomatsu T., Tabata M., Oike Y.: Angiopoietin-like proteins:emerging targets for treatment of obesity and related metabolicdiseases. FEBS J., 2011; 278: 559-564
  Google Scholar
• 48. Kapturczak M.H., Meier-Kriesche H.U., Kaplan B:. Pharmacologyof calcineurin antagonists. Transplant. Proc., 2004; 36 (Suppl.2): 25S-32S
  Google Scholar
• 49. Keating G.M.: Abatacept: a review of its use in the managementof rheumatoid arthritis. Drugs, 2013; 73: 1095-1119
  Google Scholar
• 50. Kemper M.J., Meyer-Jark T., Lilova M., Müller-Wiefel D.E.: CombinedT – and B-cell activation in childhood steroid-sensitive nephroticsyndrome. Clin. Nephrol., 2003; 60: 242-247
  Google Scholar
• 51. Kim E.Y., Anderson M., Wilson C., Hagmann H., Benzing T., DryerS.E.: NOX2 interacts with podocyte TRPC6 channels and contributesto their activation by diacylglycerol: essential role of podocinin formation of this complex. Am. J. Physiol. Cell Physiol., 2013;305: C960-C971
  Google Scholar
• 52. Klinger M., Mazanowska O.: Primary idiopathic glomerulonephritis:modern algorithm for diagnosis and treatment. Pol. Arch.Med. Wewn., 2008; 118: 567-571
  Google Scholar
• 53. Kriz W., Elger M., Mundel P., Lemley K.V.: Structure-stabilizingforces in the glomerular tuft. J. Am. Soc. Nephrol., 1995; 5: 1731-1739
  Google Scholar
• 54. Kriz W., Shirato I., Nagata M., LeHir M., Lemley K.V.: The podocyte›s response to stress: the enigma of foot process effacement.Am. J. Physiol. Renal Physiol., 2013; 304: F333-F347
  Google Scholar
• 55. Lai K.W., Wei C.L., Tan L.K., Tan P.H., Chiang G.S., Lee C.G., JordanS.C., Yap H.K.: Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J. Am. Soc. Nephrol., 2007; 18: 1476-1485
  Google Scholar
• 56. Lennon R., Singh A., Welsh G.I., Coward R.J., Satchell S., Ni L.,Mathieson P.W., Bakker W.W., Saleem M.A.: Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes.J. Am. Soc. Nephrol., 2008; 19: 2140-2149
  Google Scholar
• 57. Maas R.J., Deegens J.K., Wetzels J.F.: Serum suPAR in patientswith FSGS: trash or treasure? Pediatr. Nephrol., 2013; 28: 1041-1048
  Google Scholar
• 58. Machuca E., Benoit G., Antignac C.: Genetics of nephrotic syndrome:connecting molecular genetics to podocyte physiology. Hum.Mol. Genet., 2009; 18: R185-R194
  Google Scholar
• 59. Macian F.: NFAT proteins: key regulators of T-cell developmentand function. Nat. Rev. Immunol., 2005; 5: 472-484
  Google Scholar
• 60. Mansour H., Cheval L., Elalouf J.M., Aude J.C., Alyanakian M.A.,Mougenot B., Doucet A., Deschenes G.: T-cell transcriptome analysispoints up a thymic disorder in idiopathic nephrotic syndrome.Kidney Int., 2005; 67: 2168-2177
  Google Scholar
• 61. Mathieson P.W.: Minimal change nephropathy and focal segmentalglomerulosclerosis. Semin. Immunopathol., 2007; 29: 415-426
  Google Scholar
• 62. McCarthy E.T., Sharma M., Savin V.J.: Circulating permeabilityfactors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.Clin. J. Am. Soc. Nephrol., 2010; 5: 2115-2121
  Google Scholar
• 63. McLaughlin P., White C.A., Grillo-López A.J., Maloney D.G.: Clinicalstatus and optimal use of rituximab for B-cell lymphomas.Oncology, 1998; 12: 1763-1769
  Google Scholar
• 64. Meyer T.N., Schwesinger C., Wahlefeld J., Dehde S., KerjaschkiD., Becker J.U., Stahl R.A., Thaiss F.: A new mouse model of immune–mediated podocyte injury. Kidney Int., 2007; 72: 841-852
  Google Scholar
• 65. Morigi M., Buelli S., Angioletti S., Zanchi C., Longaretti L., ZojaC., Galbusera M., Gastoldi S., Mundel P., Remuzzi G., Benigni A.: Inresponse to protein load podocytes reorganize cytoskeleton andmodulate endothelin-1 gene: implication for permselective dysfunctionof chronic nephropathies. Am. J. Pathol., 2005; 166: 1309-1320
  Google Scholar
• 66. Munyentwali H., Bouachi K., Audard V., Remy P., Lang P., MojaatR., Deschenes G., Ronco P.M., Plaisier E.M., Dahan K.Y.: Rituximab isan efficient and safe treatment in adults with steroid-dependentminimal change disease. Kidney Int., 2013; 83: 511-516
  Google Scholar
• 67. Okamura K., Dummer P., Kopp J., Qiu L., Levi M., Faubel S., BlaineJ.: Endocytosis of albumin by podocytes elicits an inflammatoryresponse and induces apoptotic cell death. PLoS One, 2013; 8: e54817
  Google Scholar
• 68. Pescovitz M.D.: Rituximab, an anti-cd20 monoclonal antibody:history and mechanism of action. Am. J. Transplant., 2006; 6: 859-866
  Google Scholar
• 69. Pippin J.W., Glenn S.T., Krofft R.D., Rusiniak M.E., Alpers C.E.,Hudkins K.L., Duffield J.S., Gross K.W., Shankland S.J.: Cells of reninlineage take on a podocyte phenotype in aging nephropathy. Am. J.Physiol. Renal Physiol., 2014; 306: F1198-F1209
  Google Scholar
• 70. Quintá H.R., Galigniana N.M., Erlejman A.G., Lagadari M., Piwien-Pilipuk G., Galigniana M.D.: Management of cytoskeleton architectureby molecular chaperones and immunophilins. Cell Signal.,2011; 23: 1907-1920
  Google Scholar
• 71. Ransom R.F., Lam N.G., Hallett M.A., Atkinson S.J., Smoyer W.E.:Glucocorticoids protect and enhance recovery of cultured murinepodocytes via actin filament stabilization. Kidney Int., 2005; 68:2473-2483
  Google Scholar
• 72. Ravani P., Ponticelli A., Siciliano C., Fornoni A., Magnasco A., SicaF., Bodria M., Caridi G., Wei C., Belingheri M., Ghio L., Merscher-GomezS., Edefonti A., Pasini A., Montini G. i wsp.: Rituximab is a safeand effective long-term treatment for children with steroid andcalcineurin inhibitor-dependent idiopathic nephrotic syndrome.Kidney Int., 2013; 84: 1025-1033
  Google Scholar
• 73. Reiser J., Mundel P.: Danger signaling by glomerular podocytesdefines a novel function of inducible B7-1 in the pathogenesisof nephrotic syndrome. J. Am. Soc. Nephrol., 2004; 15: 2246-2248
  Google Scholar
• 74. Reiser J., Oh J., Shirato I., Asanuma K., Hug A., Mundel T.M., HoneyK., Ishidoh K., Kominami E., Kreidberg J.A., Tomino Y., Mundel P.:Podocyte migration during nephrotic syndrome requires a coordinatedinterplay between cathepsin L and α3 integrin. J. Biol. Chem.,2004; 279: 34827-34832
  Google Scholar
• 75. Reiser J., von Gersdorff G., Loos M., Oh J., Asanuma K., Giardino L.,Rastaldi M.P, Calvaresi N., Watanabe H., Schwarz K., Faul C., KretzlerM., Davidson A., Sugimoto H., Kalluri R., Sharpe A.H., Kreidberg J.A.,Mundel P.: Induction of B7-1 in podocytes is associated with nephroticsyndrome. J. Clin. Invest., 2004; 113: 1390-1397
  Google Scholar
• 76. Salmon A.H., Neal C.R., Harper S.J.: New aspects of glomerularfiltration barrier structure and function: five layers (at least) notthree. Curr. Opin. Nephrol. Hypertens., 2009; 18: 197-205
  Google Scholar
• 77. Schönenberger E., Ehrich J.H., Haller H., Schiffer M.: The podocyteas a direct target of immunosuppressive agents. Nephrol. Dial.Transplant., 2011; 26: 18-24
  Google Scholar
• 78. Sellier-Leclerc A.L., Macher M.A., Loirat C., Guérin V., WatierH., Peuchmaur M., Baudouin V., Deschenes G.: Rituximab efficiencyin children with steroid-dependent nephrotic syndrome. Pediatr.Nephrol., 2010; 25: 1109-1115
  Google Scholar
• 79. Shankland S.J., Anders H.J., Romagnani P.: Glomerular parietalepithelial cells in kidney physiology, pathology, and repair. Curr.Opin. Nephrol. Hypertens., 2013; 22: 302-309
  Google Scholar
• 80. Sharma M., Sharma R., McCarthy E.T., Savin V.J.: “The FSGS factor”:enrichment and in vivo effect of activity from focal segmentalglomerulosclerosis plasma. J. Am. Soc. Nephrol., 1999; 10: 552-561
  Google Scholar
• 81. Shimada M., Araya C., Rivard C., Ishimoto T., Johnson R.J., GarinE.H.: Minimal change disease: a “two-hit” podocyte immune disorder?Pediatr. Nephrol., 2011; 26: 645-649
  Google Scholar
• 82. Simon D., Simon H.U.: New drug targets in atopic dermatitis.Chem. Immunol. Allergy, 2012; 96: 126-131
  Google Scholar
• 83. Smith H.W., Marshall C.J.: Regulation of cell signalling by uPAR.Nat. Rev. Mol. Cell Biol., 2010; 11: 23-36
  Google Scholar
• 84. Srivastava T., Sharma M., Yew K.H., Sharma R., Duncan R.S.,Saleem M.A., McCarthy E.T., Kats A., Cudmore P.A., Alon U.S., HarrisonC.J.: LPS and PAN-induced podocyte injury in an in vitro modelof minimal change disease: changes in TLR profile. J. Cell Commun.Signal., 2013; 7: 49-60
  Google Scholar
• 85. Sugimoto H., Mundel T.M., Sund M., Xie L., Cosgrove D., KalluriR.: Bone-marrow-derived stem cells repair basement membrane collagendefects and reverse genetic kidney disease. Proc. Natl. Acad.Sci. USA, 2006; 103: 7321-7326
  Google Scholar
• 86. Taylor R.P., Lindorfer M.A.: Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol., 2008; 20: 444-449
  Google Scholar
• 87. Thuno M., Macho B., Eugen-Olsen J.: suPAR: the molecular crystalball. Dis. Markers, 2009; 27: 157-172
  Google Scholar
• 88. Tipping P.G.: Are podocytes passive or provocative in proteinuricglomerular pathology? J. Am. Soc. Nephrol., 2008; 19: 651-653
  Google Scholar
• 89. Tolosano E., Fagoonee S., Morello N., Vinchi F., Fiorito V.: Hemescavenging and the other facets of hemopexin. Antioxid. Redox Signal.,2010; 12: 305-320
  Google Scholar
• 90. van den Berg J.G., Aten J., Chand M.A., Claessen N., Dijkink L.,Wijdenes J., Lakkis F.G., Weening J.J.: Interleukin-4 and interleukin-
  Google Scholar
• 91. van den Berg J.G., Weening J.J.: Role of the immune system inthe pathogenesis of idiopathic nephrotic syndrome. Clin. Sci., 2004;107: 125-136
  Google Scholar
• 92. Vogelmann S.U., Nelson W.J., Myers B.D., Lemley K.V.: Urinaryexcretion of viable podocytes in health and renal disease. Am. J.Physiol. Renal Physiol., 2003; 285: F40-F48
  Google Scholar
• 93. Wada T., Pippin J.W., Nangaku M., Shankland S.J.: Dexamethasone’sprosurvival benefits in podocytes require extracellular signal-regulated kinase phosphorylation. Nephron Exp. Nephrol.,2008; 109: e8-e19
  Google Scholar
• 94. Wei C., El Hindi S., Li J., Fornoni A., Goes N., Sageshima J., Maiguel D., Karumanchi S.A., Yap H.K., Saleem M., Zhang Q., NikolicB., Chaudhuri A., Daftarian P., Salido E. i wsp.: Circulating urokinasereceptor as a cause of focal segmental glomerulosclerosis. Nat.Med., 2011; 17: 952-960
  Google Scholar
• 95. Wei C., Möller C.C., Altintas M.M., Li J., Schwarz K., ZacchignaS., Xie L., Henger A., Schmid H., Rastaldi M.P., Cowan P., Kretzler M.,Parrilla R., Bendayan M., Gupta V., Nikolic B., Kalluri R., Carmeliet P.,Mundel P., Reiser J.: Modification of kidney barrier function by theurokinase receptor. Nat. Med., 2008; 14: 55-63
  Google Scholar
• 96. Xing C.Y., Saleem M.A., Coward R.J., Ni L., Witherden I.R., MathiesonP.W.: Direct effects of dexamethasone on human podocytes.Kidney Int., 2006; 70: 1038-1045
  Google Scholar
• 97. Yan K., Kudo A., Hirano H., Watanabe T., Tasaka T., Kataoka S.,Nakajima N., Nishibori Y., Shibata T., Kohsaka T., Higashihara E., TanakaH., Watanabe H., Nagasawa T., Awa S.: Subcellular localizationof glucocorticoid receptor protein in the human kidney glomerulus.Kidney Int., 1999; 56: 65-73
  Google Scholar
• 98. Yap H.K., Cheung W., Murugasu B., Sim S.K., Seah C.C., JordanS.C.: Th1 and Th2 cytokine mRNA profiles in childhood nephroticsyndrome: evidence for increased IL-13 mRNA expression in relapse.J. Am. Soc. Nephrol., 1999; 10: 529-537
  Google Scholar
• 99. Yu C.C., Fornoni A., Weins A., Hakroush S., Maiguel D., SageshimaJ., Chen L., Ciancio G., Faridi M.H., Behr D., Campbell K.N., Chang J.M.,Chen H.C., Oh J., Faul C. i wsp.: Abatacept in B7-1-positive proteinurickidney disease. N. Engl. J. Med., 2013; 369: 2416-2423
  Google Scholar
• 100. Yu M., Ren Q., Yu S.Y.: Role of nephrin phosphorylation inductedby dexamethasone and angiotensin II in podocytes. Mol. Biol.Rep., 2014; 41: 3591-3595
  Google Scholar
• 101. Yu S., Li Y.: Dexamethasone inhibits podocyte apoptosis by stabilizingthe PI3K/Akt signal pathway. Biomed. Res. Int., 2013; 2013:326986
  Google Scholar
• 102. Zhang B., Shi W., Ma J., Sloan A., Faul C., Wei C., Reiser J., YangY., Liu S., Wang W.: The calcineurin-NFAT pathway allows for urokinasereceptor-mediated beta3 integrin signaling to cause podocyteinjury. J. Mol. Med., 2012; 90: 1407-1420
  Google Scholar
• 103. Zhang C., Hu J.J., Xia M., Boini K.M., Brimson C., Li P.L.: Redoxsignaling via lipid raft clustering in homocysteine-induced injury ofpodocytes. Biochim. Biophys. Acta, 2010; 1803: 482-491
  Google Scholar
• 104. Zhang S.Y., Audard V., Fan Q., Pawlak A., Lang P., Sahali D.:Immunopathogenesis of idiopathic nephrotic syndrome. Contrib.Nephrol., 2011; 169: 94-106
  Google Scholar
• 105. Zhu P., Goh Y.Y., Chin H.F., Kersten S., Tan N.S.: Angiopoietin–like 4: a decade of research. Biosci. Rep., 2012; 32: 211-219
  Google Scholar

Pełna treść artykułu